Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | EVP, CHIEF HR OFFICER | February 27, 2026 | March 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date February 27, 2026 · Filed March 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 7,914 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Tax withholding · Disposed 1,594 · Balance 7,914 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2026 Filed Mar 6, 2026 22:02 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 1,594 | $232.08 | $369,935.52 |
DisclosureSEC source: 0002078592-26-000004 · form4-03062026_100324.xml · nonDerivative · entry 1 Crum Demetris D · CIK 0002078592 · EVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,914 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 23:35 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to buy) · Derivative | 13,406 | $0.00 Strike: $230.04 | $0.00 |
DisclosureSEC source: 0002078592-26-000002 · form4-02202026_060208.xml · derivative · entry 3 Crum Demetris D · CIK 0002078592 · EVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,406 Underlying: Common Stock · 13,406 shares Expires 2036-02-17 F3 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,469 on February 18, 2027, 4,469 on February 18, 2028, and 4,468 on February 18, 2029. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 23:35 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,244 | $0.00 | $0.00 |
DisclosureSEC source: 0002078592-26-000002 · form4-02202026_060208.xml · nonDerivative · entry 2 Crum Demetris D · CIK 0002078592 · EVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,508 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 23:35 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,216 | $0.00 | $0.00 |
DisclosureSEC source: 0002078592-26-000002 · form4-02202026_060208.xml · nonDerivative · entry 1 Crum Demetris D · CIK 0002078592 · EVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,264 F1 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.